ESMO 2022 | CodeBreaK 200: sotorasib versus docetaxel in pretreated KRAS G12C-mutant NSCLC

Melissa Johnson, MD, Sarah Cannon Research Institute, Nashville, TN, provides an overview of the Phase III CodeBreaK 200 trial (NCT04303780), which compared sotorasib, an irreversible KRAS G12C inhibitor, with docetaxel in patients with KRAS G12C-mutatant advanced non-small cell lung cancer (NSCLC). The primary endpoint, progression-free survival (PFS), was met in patients receiving sotorasib and the drug was additionally better tolerated than docetaxel. Dr Johnson also comments on the potential addition of a CTLA-4 inhibitor as seen in the Phase III POSEIDON trial (NCT03164616). This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.